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Background and purpose: Lonidamine is a hexokinase II inhibitor, works as an anticancer molecule, and is 
extensively explored in clinical trials. Limited information prevails about the stability-indicating methods 
which could determine the forced degradation of lonidamine under stressed conditions. Hence, we report the 
use of a rapid, sensitive, reproducible, and highly accurate liquid chromatography and mass spectrometry 
method to analyze lonidamine degradation.  
Experimental approach: The Xbridge BEH shield reverse phase C18 column (2.5 µm, 4.6 × 75 mm) using 
isocratic 50:50 water: acetonitrile with 0.1% formic acid can detect lonidamine with help of mass spectrometer 
in tandem with an ultraviolet (UV) detector at 260 nm wavelength.   
Findings/ Results: A linear curve with r² > 0.99 was obtained for tandem liquid chromatography-mass 
spectrometry (LC-MS)-UV based detections. This study demonstrated (in the present set up of isocratic 
elution) that LC-MS based detection has a relatively high sensitivity (S/N (10 ng/mL): 220 and S/N (20 
ng/mL): 945) and accuracy at lower detection and quantitation levels, respectively. In addition to developing 
the LC-MS method, we also report that the current method is stability-indicating and shows that lonidamine 
gets degraded over time under all three stress conditions; acidic, basic, and oxidative.  
Conclusion and implications: LC-MS based quantitation of lonidamine proved to be a better method 
compared to high-performance liquid chromatography (HPLC)-UV detections for mapping lonidamine 
degradation. This is the first report on the stability-indicating method for studying the forced degradation of 
lonidamine using LC-MS method.  
 




Approximately 1.7 million U.S. individuals 
are diagnosed with cancer each year and nearly 
half will die from the disease, according to data 
from the National Institute of Health (1,2). The 
rapidly growing nature of cancer cells indicates 
that cancer is an energy-dependent phenomenon. 
In the late 1990s, it was suggested that this rapid 
proliferation resulted from increased expression 
of genes coding for glucose transporters and 
glycolytic enzymes in tumor cells (3).  
The glycolysis hypothesis provided an 
opportunity for cancer researchers to explore 
the use of novel and targeted therapies (4,5). In 
particular, they targeted hexokinase II (HKII), a 
protein that performs catalysis of the first step 
of glycolysis. Along with porin (a 
mitochondrial protein), it prevents the release 
of cytochrome C during apoptosis cascade. 
Research showed that the depletion of HKII in 
cancer cells increases the concentration of 
reactive oxygen species (ROS), which leads to 
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Furthermore, the presence of certain HKII 
inhibitors causes detachment of HKII enzyme 
from mitochondria, which leads to cell death by 
a drastic reduction in ATP (7,8). This makes 
HKII protein an important drug target for next-
generation anticancer therapy. Three molecules 
that inhibit HKII have been studied for their 
anticancer effects including 2-deoxyglucose,       
3-bromopyruvate, and clotrimazole (5).  
Researchers have also studied the anticancer 
potential of lonidamine (2-indole-carboxylic 
acid) as HKII inhibitor. It selectively reduces 
glycolysis of tumor cells, possibly by inhibiting 
mitochondrial-bound hexokinase, which is 
absent in normal differentiated cells (9,10). 
Lonidamine also reduces lactate production in 
B-cell chronic leukemia, possibly due to 
reduced cellular ATP (which is required for 
glycolysis) (11). Furthermore, lonidamine has 
been shown to improve the sensitivity of cancer 
cells to known anticancer drugs such as 
doxorubicin, cisplatin, melphalan, and others 
(12-15). As a result, this molecule was explored 
in phase I and II clinical trials in combination 
therapy against breast cancer, glioblastoma 
multiforme, ovarian cancer, and lung cancer 
(16). Lonidamine was well-tolerated but 
limited by poor bioavailability after oral 
administration.  
In light of this poor bioavailability, 
lonidamine is currently been explored in 
microencapsulation and targeted nanoparticle-
based strategies to improve its delivery (17-18). 
Current methods for quantifying lonidamine are 
limited, particularly at the lower concentrations 
employed in preclinical experiments. 
Lonidamine is usually quantified using 
conventional high-performance liquid 
chromatography (HPLC) assays in biological 
fluids and samples (19). Most HPLC methods 
have relatively high limits of detection and 
quantitation levels, indicating relatively low 
sensitivities at lower concentrations (20-22). 
Newer high-resolution mass spectrometers and 
ultra HPLC systems can aid in developing 
highly sensitive assays for the quantitation of 
lonidamine. To the best of our knowledge,                   
LC-MS method has not been used to quantify 
lonidamine for analytical applications. 
Furthermore, the best-known method for 
studying the stability study of lonidamine was 
conducted with HPLC with limited information 
about the degradation profile of lonidamine. 
Our research indicates that LC-MS based 
methods for quantitation of pharmaceutical 
active ingredients and their metabolites can 
prove to be significantly sensitive (23,24). In 
the current work, we demonstrated a highly 
sensitive LC-MS method for quantitating 
lonidamine using single or selected ion 
monitoring (SIM) mode. Results showed 
improved sensitivity of LC-MS over HPLC-
ultraviolet (UV) detection. Finally, the assay 
was used to quantitatively assess the 
degradation profile of lonidamine under strong 
acidic, basic, oxidative stress conditions.  
 
MATERIALS AND METHODS 
 
Chemicals and reagents 
Lonidamine was procured from Sigma 
Aldrich (St. Louis, MO, USA). LC-MS grade 
acetonitrile, water, and formic acid were 
purchased from Fischer Scientific (Fair Lawn, 
NJ, USA). XBridge C18 reverse phase (RP) 
HPLC column was procured from Waters Corp. 
(Milford, MA, USA). Sodium hydroxide pellets 
NF, hydrochloric acid, and hydrogen peroxide 
were purchased from Fisher Chemicals                         
(Fair Lawn, NJ, USA). 
 
Liquid chromatography conditions 
A lonidamine quantitation assay was 
established using an isocratic elution method 
with 50:50 acetonitrile with 0.1% formic acid 
and water with 0.1% formic acid as a mobile 
phase. The sample injection was set to 20 µL 
with a flow rate of 0.350 mL/min. The 
temperature of the column was maintained at  
30 °C with constant data acquisition for 20 min 
of run time. Ultra-high-performance LC-MS 
(UHPLC-MS) in tandem with UV (260 nm 
wavelength) was used for developing                                  
the quantitation method. Here, a Dionex                          
3000 UHPLC system (USA) was used for 
developing the tandem UHPLC-MS-UV 
method. The HPLC was a quaternary pump 
system with autosampler, column oven, and 
temperature-controlled sample tray. Exactive        
(v 1.1SP6) software was used for MS method 
development and data acquisition. Thermo 
Excaliber (v 3.0.63) was used for the 
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integration of Chromeleon and Exactive for 
sample injections and LC-MS data acquisition 
in .raw format. 
 
Mass spectrometry conditions 
For identification of analyte (lonidamine) in 
solution eluting out of the HPLC column, a 
mass scanning range of 100 to 322 m/z was 
used. All scans were performed under positive 
ion mode. The sheath gas flow rate was 
maintained at 30 psi with an electron spray 
ionization voltage of 3.50 kV and a capillary 
temperature of 380 °C. Capillary, tube lens, and 
skimmer voltages were maintained at 45, 85, 
and 18 V, respectively. These parameters were 
adjusted using the auto-tune function of 
Thermo Exactive (v. 1.1 Sp6) software by 
direct infusion of lonidamine in the mass 
spectrometer. Using this function, the software 
automatically adjusts the parameters mentioned 
above to optimize the signal-to-noise (S/N) 
ratio (around 107 units) for lonidamine. Hence, 
an offline MS method was developed for the 
identification of lonidamine, which was then 




Primary stocks of lonidamine were prepared 
in methanol (LC-MS grade) at a concentration 
of 1 mg/mL and stored at -20 °C. This aliquot 
was used for making secondary stock of                         
10 µg/mL. Later, the secondary stock solution 
was serially diluted in the concentration range 
of 10 to 10,000 ng/mL. All the serially diluted 
samples were stored at 4 °C for inter-day runs. 
All inter- and intra-day runs were performed at 
20 °C. All the serially diluted samples were 
subjected to LC-MS-UV tandem runs. 
 
Linearity 
A linearity curve (for LC-MS and                      
HPLC-UV) was prepared for the calibration 
standard samples (10 to 10,000 ng/mL) using 
values from three independent day runs, with 
two repeated injection for each set, n = 6 (3 × 
2) injections. While developing the quantitation 
assay, the acceptable mean value of estimated 
concentration (% accuracy or recovery) for 
calibration and validation standards were kept 
within ± 15% to ± 20% of the theoretical value 
(25). The mean value of the lower limit of 
quantitation (LLOQ) was set within ± 10% 
coefficient of variance (CV). For other (higher) 
concentrations, this limit was set to ± 5% CV. 
According to Moorthy et al. at least 75% of the 
non-zero standards should meet these criteria 
and the linear coefficient of determination (r2) 
should be ≥ 0.99 (26). A linear regression                
(Y = mX + C) equation was determined for both 
data sets from concentration vs area of 
calibration standards. A linear regression 
equation from LC-MS standard runs was used 
to determine the time-dependent degradation of 
lonidamine under various forced degradation 
conditions. 
 
Validation and stability 
The quantitative method for LC-MS was 
validated for inter- and intra-day accuracy, 
%CV, and stability. Validation of the method 
was carried out using quality control (QC) 
standards of four random concentrations (80, 
200, 3000, and 8000 ng/mL). Measurements 
were made for inter- and intra-day %CV and % 
accuracy. Furthermore, to check the stability of 
solutions, LC-MS analysis for lonidamine at 
various concentrations (20, 40, 500, and 10,000 
ng/mL) were performed after freeze (-20°C)-
thaw cycles. 
 
Acid degradation studies of lonidamine 
Preliminary studies have shown that 
lonidamine degrades at 1 µg/mL under 1 N HCl 
at 40 °C (28,29). Hence to assess the rate of 
degradation and probable degradation peaks of 
lonidamine, it was subjected to forced 
degradation with 1 N HCl under 40 and 80 °C 
with a final volume of solution as 10 mL. 
Samples (100 µL) were withdrawn at specific 
time (0, 6, 24, 48, and 72 h) points, centrifuged 
at 15,700 g for 10 min, and subjected to LC-MS 
runs to identify probable degradation 
chromatograms. 
 
Alkali degradation studies of lonidamine  
Similar to acidic degradation, lonidamine 
can also degrade under alkaline conditions. In 
order to assess the degradation process, 
lonidamine was treated with 1 N NaOH under 
40 and 80 °C with a final volume (of solution) 
of 10 mL. Samples (100 µL) were withdrawn at 
Lonidamine stability-indicating assay using LC-MS   
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specific time (0, 6, 24, 48, and 72 h) points, 
centrifuged at 15,700 g for 10 min, and 
subjected to LC-MS runs to identify probable 
degradation peaks in the chromatogram. 
 
Oxidative degradation studies 
Finally, lonidamine was subjected to oxidizing 
degradation using concentrated H2O2 with a 
sample volume of 10 mL (27,28). Samples were 
subjected to temperature treatment at 40 °C. 
Samples (100 µL) were withdrawn at specific 
time (0, 6, 24, and 48 h) points, centrifuged at 
15,700 g for 10 min, and subjected to LC-MS runs 
to identify degradation profile. 
 
Statistical analysis 
Two tailed student’s t-test was used for the 
comparative analysis between data of interest. 
Wherever possible data is presented as                   
mean ± standard deviation along with                             
the respective P values. 
RESULTS 
 
Method development for the quantitative 
determination of lonidamine 
The retention time of standard lonidamine 
was found to be 12.34 ± 0.4 min with selected 
or targeted mass (M+H) + ion as 321.02 m/z, as 
shown in Fig. 1. The linearity equation                      
(Y = 32792X) was established with correlation 
coefficient (r2) 0.9959. The average accuracy of 
inter- and intra-day run was found to be 88.14 
± 0.568% to 115.577 ± 0.469%, respectively. In 
the case of LC-MS method, although the signal 
intensity was detectable at 20 ng/mL, the % 
accuracy dropped below 100 ± 20%. Hence, for 
LC-MS assay, 10 ng/mL and 20 ng/mL were 
considered as LLOD and LLOQ, respectively. 
The tandem UV absorbance linearity equation 
(Y = 162.86X) was also found to have                             
r2 = 0.9999 with average accuracy in the range 
of 90.84 ± 6.60% to 100.90 ± 0.31%. 
 
 
Fig. 1. Representative (A) TIC of lonidamine, (B) XIC-LC-MS chromatogram of lonidamine, (C) tandem HPLC-UV 
chromatogram, and (D) corresponding mass spectra of lonidamine with target mass ion (M+H)+ as 321.02 m/z. TIC, 
Total Ion chromatogram; XIC, extracted Ion chromatogram; LC-MS, liquid chromatography-mass spectrometry; HPLC, 
high-performance liquid chromatography; UV, ultraviolet. 
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Table 1. The CV and accuracy for the calibration standards used for plotting calibration curves for lonidamine using 
LC-MS runs, and tandem HPLC runs of lonidamine (with UV base detection) for its quantitation. Detection for the 




Inter-day, n = 6 Intra-day, n = 2 Accuracy (%) 
Inter-day, n = 6 
Accuracy (%) 
Intra-day, n = 2 CV (%) Area ± SD CV (%) Area ± SD 
20 1.61 412178 ± 6618 3.56 416858 ±14826 62.85 ± 1.01 63.56 ± 2.26 
40 2.28 1314465 ± 29937 2.23 1335634 ± 29745 100.21 ± 2.28 101.82 ± 2.27 
50 1.28 1693037 ± 21619 1.01 1708324 ± 17188 103.30 ± 1.32 104.19 ± 1.05 
100 1.30 2877082 ± 37260 3.15 2903429 ± 91380 87.74 ± 1.14 88.54 ± 2.79 
500 0.74 18570382 ± 138042 2.10 18667992 ± 392568 113.26 ± 0.84 113.86 ± 2.39 
1000 1.27 37098195 ± 471480 1.81 37431582 ± 678901 113.13 ± 1.44 114.15 ± 2.07 
2000 0.81 75582289 ± 615255 1.36 76017341 ± 1030986 115.24 ± 0.94 115.91 ± 1.57 
5000 1.25 177493941 ± 2220627 1.68 179064161 ± 3005901 108.25 ± 1.35 109.21 ± 1.38 
10000 0.87 318617153 ± 2779019 4.16 320582216 ± 13341608 97.16 ± 0.85 97.76 ± 4.07 
HPLC-UV 
100 124.7 8032 ± 10020 141.4 4836 ± 6840 49.32 ± 61.57 29.67 ± 42.00 
500 7.12 80743 ± 5746 0.41 81475 ± 338 99.16 ± 7.05 100.05 ± 0.41 
1000 8.70 155543 ± 13533 8.13 140343 ± 11411 95.51 ± 8.31 86.17 ± 7.01 
2000 0.39 325148 ± 1266 2.34 324296 ± 7596 99.82 ± 0.38 99.56 ± 2.33 
5000 1.75 823416 ± 14412 1.61 819876 ± 13223 101.1 ± 1.76 100.68 ± 1.62 
10000 1.08 1624961 ± 17589 1.09 1623112 ± 17635 99.78 ± 1.07 99.66 ± 1.08 
Con., Concentration; SD, standard deviation; CV, Coefficient of variance; LC-MS, chromatography-mass 





Fig. 2. Representative XIC-LC-MS for (A) LLOD (S/N: 220) as 10 ng/mL and LLOQ (S/N: 945) as 20 ng/mL for 
lonidamine and (B) shows representative LLOD (S/N: 1) as 100 ng/mL and LLOQ (S/N:4) as 500 ng/mL for the                     
HPLC-UV quantitation method. XIC, Extracted Ion chromatogram; LC-MS, liquid chromatography-mass spectrometry; 
LLOD, lower limit of detection; LLOQ, lower limit of quantitation; HPLC, high-performance liquid chromatography; 
UV, ultraviolet. 
 
The accuracy% and CV% data for the linearity 
curve from LC-MS-UV tandem runs are 
summarized in Table 1. In case of HPLC-UV 
assay, the % accuracy dropped below 100 ± 20 % 
at concentrations below 500 ng/mL. Hence, 100 
ng/mL (49.32 % accuracy) and 500 ng/mL 
(99.15% accuracy) were considered as LLOD and 
LLOQ for the assay. The relative sensitivity of 
LC-MS (Fig. 2A) was found to be higher 
compared to HPLC-UV (Fig. 2B) detections.  
Hence, looking at the % accuracy values for both 
LC-MS and HPLC-UV runs, linearity curve was 
established in the range of 20 to 10,000 ng/mL 
and 500 to 1000 ng/mL, respectively.  







Fig. 3. (A) Degradation of lonidamine in 1 N HCl at 40 and 80 °C, respectively. *P < 0.05 indicates significant differences 
between every two points regarding their corresponding time pint. Overall data suggest that lonidamine was degraded 
significantly at 80°C under 1N HCl; (B and C) chromatograms of lonidamine at 40 and 80 °C, respectively, at specific 
time points showing the relative degradation pattern in 1 N HCl; and (D) chromatograms of probable degradation peak 
vs standard and blank 1 N HCl.  
 
Validation and stability testing of LC-MS 
method for the quantitation of lonidamine 
The LC-MS method and the calibration 
curve were validated using random known 
concentrations of lonidamine. Table 2                     
shows the data (accuracy% and CV%)                         
for the validation runs. The accuracy for inter- 
and intra-day runs was found to be in                               
the range of 93.36 ± 1.07% and 115.13 ± 
2.50%, respectively. The intra- and inter-day 
validation results for random concentrations 
showed CV (< 5%) in the range of 0.99 ± 1.16% 
to 3.68 ± 1.14%. Furthermore, stability                
testing (for freeze-thaw cycles) of lonidamine 
solution using four additional random 
concentrations showed accuracy around                  
100 ± 20% and CV < 10% shown in Table 3. 
This indicates that the present method                            
of LC-MS may serve to be optimum                                
for the quantitation of degradation peaks                     
in the stability-indicating method for 
lonidamine. 
 
Forced degradation of lonidamine in the 
presence of strong acid. 
Due to exposure of lonidamine to 1 N HCl 
caused a time-dependent reduction in the 
concentration of the parent ion peak. This 
reduction was increased on a temperature-
dependent basis as shown in Fig. 3.                             




Inter-day, n = 3 Intra-day, n = 2 Accuracy (%)  
Inter-day (n = 3) 
Accuracy (%)  
Intra-day (n = 2) CV (%) Area ± SD CV (%) Area ± SD 
80 2.871 2742049 ± 78827 0.17 2679149 ± 4575 104.52 ± 3.00 102.13 ± 0.17 
200 2.26 7360566 ± 166086 4.48 7257893 ± 324949 112.23 ± 2.53 110.67 ± 4.95 
3000 2.371 104886880 ± 2482132 1.75 102973246 ±1801549 106.62 ± 2.52 104.67 ± 1.83 
8000 1.82 246914062 ± 4488524 2.41 242932821 ± 5858593 94.12 ± 1.71 92.60 ± 2.23 
Con., Concentration; SD, standard deviation, CV, Coefficient of variance; LC-MS, chromatography-mass spectrometry. 




The degradation of lonidamine was relatively 
higher at 80 °C (P < 0.05) after 20 h of 
incubation.  The overall degradation of 
lonidamine was significantly (P < 0.05) higher 
at 80 °C in comparison to 40 °C in 1 N HCl. 
Degradation peak was also identified in the 
mass range 276 to 277 m/z (Fig. 3) at the 
retention time of 1.88 min. 
 
Forced degradation of lonidamine in the 
presence of a strong base 
As shown in Fig. 4, it was observed that 
lonidamine gets degraded in basic (1N NaOH) 
condition showed a temperature-independent 
effect. It was detected that parent ion peak 
quantitatively reduced upon incubation of 
lonidamine in 1N NaOH. Later, it got 
significantly degraded within the first 6 h                       
(P < 0.05) of incubation at both 40 and 80 °C. 
Insignificant (P > 0.05), temperature-dependent 
difference was observed in the degradation 
profile of lonidamine in presence of 1 N NaOH. 
There was a subsequent rise in the degradation 
peak (Fig. 4) around 1.66 min for a mass range 
of 172 to173 m/z. 
 
Forced degradation of lonidamine in the 
presence of a strong oxidizing agent  
As shown in Fig. 5, lonidamine gets                         
forced degraded at 40 °C temperature in                              
a time-dependent manner with P < 0.05.                              
It was noted that lonidamine gets                                   
degraded by the end of a 48-h (P < 0.05)                          
time point. The lonidamine peak gets 
significantly reduced at a 48-h time                           
point and consequently the presence of 
production (171 to 172 m/z) peak increases 
around Rt = 1.60 min. 
 
 
Fig. 4. (A) Time- and temperature-dependent degradation of lonidamine in the presence of 1 N NaOH. Although it shows 
complete degradation within first 6 to 24 h of incubation (**P < 0.01), no temperature-dependent effect was observed; 
(B) representative chromatograms of lonidamine showing time-dependent degradation of drug molecule in 1 N NaOH; 
and (C) degradation peak of lonidamine vs small standard peak for the drug and blank.  
 
Table 3. The CV and accuracy (from LC-MS runs) for 
random concentration for lonidamine after freeze-
thaw cycles (n = 2). 
Concentrations 
(ng/mL) CV (%) Accuracy (%) 
20 3.41 ± 0.60 62.43 ± 0.89 
40 0.78 ± 0.20 99.19 ± 0.30 
500 1.59 ± 0.20 108.73 ± 3.68 
10000 4.89 ± 0.22 88.59 ± 1.59 
CV, Coefficient of variance; LC-MS, liquid 
chromatography-mass spectrometry. 
Lonidamine stability-indicating assay using LC-MS   
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Fig. 5. (A) Significant time-dependent degradation of lonidamine in H2O2 at 40°C with  (B) representative chromatogram 
of lonidamine showing time-dependent degradation, and (C) chromatogram of probable degradation product of 




Lonidamine is a hydrophobic anticancer 
molecule. A quantitation assay for lonidamine 
was developed using reverse phase 
chromatography. Lonidamine standards were 
subjected to LC-MS-UV runs using 
conventional isocratic elution chromatography 
with 50:50 water: acetonitrile with 0.1% formic 
acid. The present LC-MS based quantifiable 
method for lonidamine is sensitive for 
detections and quantitation in the nanogram 
concentration range (21). A UV based detection 
of eluting lonidamine (10 to 10000 ng/mL) 
standards were also used in tandem with mass 
spectrometer detection. Our results indicated 
that UV based HPLC detection could only 
provide accurate outcomes in the concentration 
range of 500 to 10000 ng/mL with a CV < 10% 
(Table 1). This observation and results are 
consistent with previously published work with 
low injection volumes (21). The result 
suggested that tandem HPLC-UV had higher 
values for lower limit of detection (LLOD), and 
the lower limit of quantitation (LLOQ) (Fig. 
2B) as compared to LC-MS (Fig. 2A). This also 
confirms that the current LC-MS method  
provided a significant improvement over 
previous HPLC based UV detection methods by 
detecting and quantitating lower concentrations 
(19,22). Ioele et al. (21) provided an HPLC 
method with a linear calibration range of 0.5 to 
50 µg/mL for lonidamine that was used for the 
qualitative impurity analysis which had 
relatively, higher LLOD and LLOQ values 
compared to the present study. Whereas, this 
study provided an online LC-MS method using 
high-resolution mass spectrometers systems                     
with high sensitivity in mass detection                         
with < 0.5 ppm error as compared to previously 
reported runs on HPLC and followed by 
separate GC-MS based confirmation of masses. 
Milane et al. (22) reported HPLC method for 
simultaneous estimation of lonidamine and 
paclitaxel from plasma and tissue samples of 
animals, where LLOD and LLOQ of 64 and                    
80 ng/mL was reported. Whereas, the present 
study data shows that with LC-MS method can 
go as low to 10 and 20 ng/mL for LLOD and 
LLOQ values. The previously published HPLC 
methods were not stability-indicating in nature. 
However, it showed that simple isocratic HPLC 
methods could be used for the efficient 
estimation of lonidamine in a complex matrix. 
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To the best of our knowledge, this is the first 
reported LC-MS method for studying the 
degradation of lonidamine. This indicated that 
the present LC-MS method provides a simple 
robust and high sensitivity-based edge for 
mapping force degradation rates of lonidamine 
under various stress conditions.  
The LC-MS (without UV detections) based 
linearity curve obtained for lonidamine 
described above were subjected to validation 
study using random (low, medium, high, and 
ultra-high) concentration ranges, as shown in 
Table 2. Intra- and inter-day validation results 
for random concentrations showed CV < 5%.  
The accuracy% for these validation standards 
for inter- and intra-day was found to be around 
100 ± 20%. These studies indicated that the 
calibration curves are robust and with high 
accuracy as per the ICH guidelines and 
previously published reports (24,29-31). 
Linearity and validation study of linearity 
provides a necessary baseline for the stability of 
drug under ambient room temperature 
conditions. Further, the stability test for four 
random concentrations (Table 3) also supported 
the validation data performed by carrying out 
freeze-thaw cycles. It was observed that the 
lonidamine molecule has excellent stability at 
freezing and ambient room temperature at low 
and high concentrations, which is consistent 
with the previous report (21). Hence, the LC-
MS based sensitive quantitation assay could be 
used for further analysis of the degradation of 
lonidamine under various forced degradation 
conditions.  
Previous studies have shown that lonidamine 
(solid and solution) degrades in the presence of 
heat and light. It provides the necessary 
information to show that this molecule in the 
solution state is thermally stable at 21 and                     
40 °C. Lonidamine thermally stressed at 70 °C 
shows the degradation peak of the drug. 
Whereas, the solid lonidamine showed high 
stability at 60 and 100 °C and authors were able 
to perform only a small part of forced 
degradation studies (17,27). The detailed 
understanding of the stability of the lonidamine 
solution state in the presence of an external 
stress inducer becomes important. Hence, we 
performed temperature-dependent degradation 
of lonidamine in the presence of strong acidic 
(1 N HCl), basic (1 N NaOH), and oxidizing 
(H2O2) conditions. 
To quantitatively estimate the degradation 
profile of lonidamine in the presence of a strong 
acid, we placed two vials containing 10 mL of 
acidified (treated with 1 N HCl) lonidamine 
solution in a water bath maintained at 40 and   
80 °C. A time-dependent decrease in the 
concentration of lonidamine could be observed 
in Fig. 3A. There was a significant increase in 
the degradation rate due to a temperature 
increase to 80 °C. This could also be confirmed 
from the stepwise reduction in lonidamine LC-
MS chromatogram peaks under two 
temperature conditions, as shown in Fig. 3B 
and C. This indicates that the degradation rate 
of lonidamine could get affected by high 
temperatures and strong acid. Lonidamine is 
degraded under temperature-dependent acid 
hydrolysis, and degradation peaks were also 
identified. The degradation peaks for 
lonidamine after 24 h is shown in Fig. 3D.   
Further, a strong degradation of the 
lonidamine solution was observed with 1 N 
NaOH. It was observed that a strong base could 
cause significant damage to the structural 
integrity of lonidamine (Fig. 4A and B). Later, 
there was a dramatic reduction in the peak of 
lonidamine and a subsequent rise in the 
degradation peak (Fig. 4C). However, all the 
values are lesser then quantitation limits, hence 
we can consider complete degradation of the 
lonidamine. 
Lonidamine degraded at both 40 and 80 °C 
under acidic and basic conditions. Taking this 
factor into consideration, lonidamine was 
treated with H2O2 and incubated at 40 °C in a 
water bath. The degradation rate of lonidamine 
was assessed at predetermined time points as 
shown in Fig. 5A and B. There was a significant 
degradation by the end of the 48-h time point. 
A degradation peak could be mapped as shown 
in Fig. 5C. The present LC-MS method could 
detect both the parent and degradation peaks (in 
the presence of 1 N HCl, 1 N NaOH, and H2O2) 
in a single run. The peaks of the parent ion 
remained uninterrupted by degradation.  
The estimation of degradation 
chromatogram was carried out in an extremely 
accurate manner with an error of < 0.5 ppm. 
These results showed that lonidamine gets 
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degraded in the presence of an acid, base, and 
strong oxidation conditions. Moreover, it was 
possible to detect the degradation peak of                    
the parent molecule, which indicates that the 
LC-MS method presented in this study is 




A highly sensitive, robust, and reproducible 
LC-MS method was developed with 
quantitation and detection limits in nanogram 
concentrations. The LLOD and LLOQ for                
LC-MS detection of lonidamine were found to 
be significantly better than the conventional 
HPLC-UV based detections and quantitation. 
Our results suggest that the current method is 
stability-indicating as it can map the 
degradation profile for lonidamine, with order 
degradation as 1 N NaOH > H2O2 > 1 N HCl. 
The stability-indicating method can help in 
studying the stability of formulations of 
lonidamine; currently being compounded for 
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